BACKGROUND: Consumption of caffeinated beverages such as coffee and tea has been associated with a lower risk of type 2 diabetes (T2D). Paradoxically, short-term metabolic studies have shown that caffeine impairs postprandial glycemic control. OBJECTIVE: The objective was to prospectively examine the association of caffeinated compared with caffeine-free beverages, including coffee, tea, sugar-sweetened beverages (SSBs), and carbonated artificially sweetened beverages (ASBs), with T2D risk. DESIGN: We prospectively observed 74,749 women from the Nurses' Health Study (NHS, 1984-2008) and 39,059 men from the Health Professionals Follow-Up Study (HPFS, 1986-2008) who were free of diabetes, cardiovascular diseases, and cancer at baseline. RESULTS: We documented 7370 incident cases of T2D during 24 y of follow-up in the NHS and 2865 new cases during 22 y of follow-up in the HPFS. After major lifestyle and dietary risk factors were controlled for, caffeinated and caffeine-free SSB intake was significantly associated with a higher risk of T2D in the NHS (RR per serving: 13% for caffeinated SSBs, 11% for caffeine-free SSBs; P < 0.05) and in the HPFS (RR per serving: 16% for caffeinated SSBs, 23% for caffeine-free SSBs; P < 0.01). Only caffeine-free ASB intake in NHS participants was associated with a higher risk of T2D (RR: 6% per serving; P < 0.001). Conversely, the consumption of caffeinated and decaffeinated coffee was associated with a lower risk of T2D [RR per serving: 8% for both caffeinated and decaffeinated coffee in the NHS (P < 0.0001) and 4% for caffeinated and 7% for decaffeinated coffee in the HPFS (P < 0.01)]. Only caffeinated tea was associated with a lower T2D risk among NHS participants (RR per serving: 5%; P < 0.0001). CONCLUSION: Irrespective of the caffeine content, SSB intake was associated with a higher risk of T2D, and coffee intake was associated with a lower risk of T2D.
BACKGROUND: Consumption of caffeinated beverages such as coffee and tea has been associated with a lower risk of type 2 diabetes (T2D). Paradoxically, short-term metabolic studies have shown that caffeine impairs postprandial glycemic control. OBJECTIVE: The objective was to prospectively examine the association of caffeinated compared with caffeine-free beverages, including coffee, tea, sugar-sweetened beverages (SSBs), and carbonated artificially sweetened beverages (ASBs), with T2D risk. DESIGN: We prospectively observed 74,749 women from the Nurses' Health Study (NHS, 1984-2008) and 39,059 men from the Health Professionals Follow-Up Study (HPFS, 1986-2008) who were free of diabetes, cardiovascular diseases, and cancer at baseline. RESULTS: We documented 7370 incident cases of T2D during 24 y of follow-up in the NHS and 2865 new cases during 22 y of follow-up in the HPFS. After major lifestyle and dietary risk factors were controlled for, caffeinated and caffeine-free SSB intake was significantly associated with a higher risk of T2D in the NHS (RR per serving: 13% for caffeinatedSSBs, 11% for caffeine-free SSBs; P < 0.05) and in the HPFS (RR per serving: 16% for caffeinatedSSBs, 23% for caffeine-free SSBs; P < 0.01). Only caffeine-free ASB intake in NHS participants was associated with a higher risk of T2D (RR: 6% per serving; P < 0.001). Conversely, the consumption of caffeinated and decaffeinated coffee was associated with a lower risk of T2D [RR per serving: 8% for both caffeinated and decaffeinated coffee in the NHS (P < 0.0001) and 4% for caffeinated and 7% for decaffeinated coffee in the HPFS (P < 0.01)]. Only caffeinated tea was associated with a lower T2D risk among NHS participants (RR per serving: 5%; P < 0.0001). CONCLUSION: Irrespective of the caffeine content, SSB intake was associated with a higher risk of T2D, and coffee intake was associated with a lower risk of T2D.
Authors: S van Dieren; C S P M Uiterwaal; Y T van der Schouw; D L van der A; J M A Boer; A Spijkerman; D E Grobbee; J W J Beulens Journal: Diabetologia Date: 2009-09-01 Impact factor: 10.122
Authors: W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer Journal: Am J Epidemiol Date: 1985-07 Impact factor: 4.897
Authors: S Salvini; D J Hunter; L Sampson; M J Stampfer; G A Colditz; B Rosner; W C Willett Journal: Int J Epidemiol Date: 1989-12 Impact factor: 7.196
Authors: Nicole M Wedick; Aoife M Brennan; Qi Sun; Frank B Hu; Christos S Mantzoros; Rob M van Dam Journal: Nutr J Date: 2011-09-13 Impact factor: 3.271
Authors: Meghan B Azad; Ahmed M Abou-Setta; Bhupendrasinh F Chauhan; Rasheda Rabbani; Justin Lys; Leslie Copstein; Amrinder Mann; Maya M Jeyaraman; Ashleigh E Reid; Michelle Fiander; Dylan S MacKay; Jon McGavock; Brandy Wicklow; Ryan Zarychanski Journal: CMAJ Date: 2017-07-17 Impact factor: 8.262
Authors: Julia S Sisti; Susan E Hankinson; Neil E Caporaso; Fangyi Gu; Rulla M Tamimi; Bernard Rosner; Xia Xu; Regina Ziegler; A Heather Eliassen Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-10 Impact factor: 4.254
Authors: Shilpa N Bhupathiraju; An Pan; JoAnn E Manson; Walter C Willett; Rob M van Dam; Frank B Hu Journal: Diabetologia Date: 2014-04-26 Impact factor: 10.122
Authors: Brendan J Guercio; Kaori Sato; Donna Niedzwiecki; Xing Ye; Leonard B Saltz; Robert J Mayer; Rex B Mowat; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Alan Venook; Frank B Hu; Shuji Ogino; Kana Wu; Walter C Willett; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544